Chediak-Higashi Syndrome: Phenotype, Genotypes, and Pathogenesis

Chediak-Higashi Syndrome (CHS) is an autosomal recessive syndrome characterized by the development of abnormally large lysosomes and associated LROs. This article discusses the phenotype, genotypes, and pathogenesis of CHS, including the genetic deficiency and structural overview of the LYST gene. It also explores the diagnosis and genotype-phenotype association of CHS.

Running head: CHEDIAK-HIGASHI SYNDROME
CHEDIAK-HIGASHI SYNDROME
Name of the Student
Name of the University
Author Note

1CHEDIAK-HIGASHI SYNDROME
Chediak-Higashi Syndrome (CHS) phenotype and Institution of Associating Genotypes
Acronyms
- CHS; Chediak Higashi Syndrome
- LRO; Lysosome-Related Organelles
- LYST; Lysosomal Trafficking Regulator Gene
- HLH; Haemophagocytic Lympho histocytosis
- PMN; Polymorphonuclear Leukocyte
- BEACH; Beige and Chediak Higashi
- PH; Pleckstrin Homology
- ARM; Armadilo
- HEAT; Huntington, EF3, PP2A and TOR1 protein domain
- IS; Immune Synapse
- CTL; Cytotoxic T-Cell
- NK; Natural Killer
- LCCA; Late Cortical Cerebellar Atrophy
- OPCA; Olivopontocerebellar Atrophy
- MRI; Magnetic Resonance Imaging
- APC; Antigen-presenting Cell
- EBV; Epstein Barr Virus
- UPD; UniparentalDisomy.
1

2CHEDIAK-HIGASHI SYNDROME
Abstract
Chediak-Higashi Syndrome (CHS) is considered as an autosomal non-dominant syndrome, presented by the
development of aberrantly huge lysosomes and associated LROs that usually collect within peri nuclear
section of the cells. The inflated vesicle dimension includes the utility of above structures, resulting in
decreased bacterial devastation, incomplete albinism, neural problems, decreased coagulation and injury
repair. The patients usually surrender to repeated bacterial contaminations, or because of the principal organs
present in the body is subjected to the lymphoma-identical intrusion. Pathogenesis of disease in CHS is
connected with alteration actions expressing in wild or harsh kind human gene, termed as LYST, disturbing
the LYST gene expression. Although the biochemical activity of LYST is inadequate and has been gambled
to get involved in controlling the LROs and lysosome size by regulating either fusion events or vesicular
fission.
2

3CHEDIAK-HIGASHI SYNDROME
Introduction
CHS is defined as an autosomal receding syndrome that is identified by flexible units of recurring
pyogenic contaminations, a predilection near minor bleeding incidents, neural dysfunction and
occulocutaneous albinism. Roughly 50 – 85% of patients suffering from CHS might feel an ‘enhanced
phase’ as portion of infection pathogenesis, connected with haemophagocytic lympho histocytosis (HLH)
that is frequently fatal if not diagnosed (4).
The genetic deficiency accountable for the above compulsive manifestations connected with CHS is
plotted to 1q42.3 chromosome, associating to the LYST gene in human. 422 kDa is total length of LYST
protein and includes highly preserved organization. Numerous ARM/HEAT α-helix replicates are situated
near the N-terminal area of protein, tracked by BEACH province and province of seven WD40 duplicates at
the domain of C-terminal (4).
The primary activity of LYST is focused to conjecture, and is considered to be connected with the
instruction of lysosome-associated organizations, comprising organelle dimension, secretion and fission. In
CHS, irregular genetic variations effect in massive cytoplasmic organelles like lysosomes, inclusion bodies
and melanosomes. Moreover, plasma membrane restoration mechanisms is subjected to resistance, in count
of the exocytic method engaged by lysosomes. A huge quantity of the figures, which permits the association
between phenotype and genotype in CHS that is extracted from the consumption of Lyst gene that is majorly
identical to the LYST human gene alternate (5).
Diagnosis
It is crucial to conduct a primary diagnosis of CHS. The usual age considered for CHS diagnosing is
nearly six years, although 25% of cases might be identified after age of 10 years. The analysis considered for
the disorder through prenatal phase is specified through the occurrence of productive phosphatase acid in the
lysosomes by amniotic liquid cells and foetus plasma leukocyte. The occurrence of large particles in the hair
tube is dangerous in diagnosis of syndrome through prenatal and antenatal phase (6). Hence, diagnosis of
CHS is entirely dependent on two different evaluations. First, the occurrence of huge positive peroxidase
particles in polymorph nuclear leukocytes (PMN) and secondly, genetic investigation of mutated gene for
LYST/CHS1 occurs in the principal chromosome. A dissimilar diagnostic research known as cytometric
fluorescence study that defines cellular surface particles and cell granules (6).
Various disorders sharing related symptoms of CHS exist. Though, they might be separated from CHS
by numerous remarks (6). Griscelli syndrome comprise of related symptoms as CHS comprising fractional
cutaneous-ophthalmic albinism, impaired phase through pancytopenia, cellular and humeral immune
insufficiency, hemophagocytosis, amplified serum triglyceride volume, reduced fibrinogens, haemorrhagic
syndrome and lessened plasma protein. Alteration develops in RAB27A and myo5a genes. Hermansky-
pudlak disease is another considered example where no huge granules is present. Platelet deposit is
exhausted related with bleeding. Respiratory fibrosis takes place. No neutrophil and defects occurs.
3

4CHEDIAK-HIGASHI SYNDROME
Furthermore, Angelman and PraderWilli are two diseases comprised of hypopigmentation and absence of
ophthalmic albinism. Pyodermagangernosome, Warrensburg disease and Lazy leukocyte disease are
considered variance diagnosis. Mental retardation, neonatal Hyperphagia and hypogonadism are existent in
praderwilli condition. In Angelman disease, acute psychological retardation, ataxia, neonatal hypotonia,
microcephaly and incorrect laughter. In Warrensburg syndrome, neural crest deficiency, piebaldism,
congenital deafness, forelock hypopigmentation and extensive nasal root is observed (6).
Functional and Structural Overview
The LYST human gene conquers a huge area on the 1q42.3 chromosome, containing 55 exons and 222
kb length (7), as portrayed in Figure 1. The protein articulated by LYST gene is included in the family
BEACH (Beige and Chediak Higashi) of proteins. Every participants included in BEACH family has the
similar preserved arrangement encompassing C-terminal areas that comprise Pleckstrin homology (PH) and
sequence of WD-40 replicates monitored by BEACH province; N-terminal province remains highly vague
(7). The BEACH province is considered as the mark element within BEACH family, which is unique and
unusual. Large sections of the province either hidden internally or aid to remove hydrophobic core from the
present construction.
Figure 1: Chromosomal mapping of LYST gene present in chromosome 1
4

5CHEDIAK-HIGASHI SYNDROME
Figure 2: The BEACH human family of proteins portrayed in respects to their province organisation.
The above provinces present at C-terminal area of BEACH family is wondered to be intricate in
compiling of protein associates, but their activity is still unidentified(7). Large statistics connecting to the
useful competences of LYST gene has been inferred through directing readings on other associates of the
descent, and the common agreement of them being related to receptor signalling, membrane dynamics and
vesicle trafficking (4).
Lately, it is exposed that lectin-like province is present in N-terminal area of BEACH family. The
lectin-alike province is ventured to initiate binding of oligosaccharide to protein trading, and also engage in
the practice of categorization beside the secretory way – this mainly relates to the essential constituents of
vesicular mixture technology (4).
Like the lectin-like province that is preserved feature in the BEACH proteins descent, the N’ end area
of LYST protein comprises numerous ARM (Armadilo)/HEAT (protein province establish in Huntingtin,
EF3, PP2A, and TOR1) α-helix recurrence motifs, precise to the present protein. Therefore, the synergistic
act of the LYST protein subunits permit them to be accountable for fission and union actions that effect the
complete dimension of the cellular arrangements, with its effect not exclusively limited to lysosomal
constructions, but also influences several alike organelles (5).
LYST is intricate in either vesicle fission or fusion with a serious part in the endolysosomal biogenesis
which controls the terminal development of secreted lysosomes
The researcher have dedicated on the trademark distended cytoplasmic organelles existent in
practically every granulated cells (1) of the sufferers with CHS. The above organelles are suggested to
establish a combination of lysosomal and endosomal structures (11), which has identical degradation ability
as compared to lysosomal (8). Though an agreement on the process of these huge organelles formation has
5

6CHEDIAK-HIGASHI SYNDROME
not reached, considering the investigation data it was exposed that LYST has a crucial character in the
endolysosomal biogenesis that controls the end development of secretive lysosomes (11). Patients with CHS
have enlarged cytotoxic granules and miscarry to issue their material at the immune synapse (IS), in spite of
a usual polarization during initiation (1). Therefore, LYST is included in decreased fission or amplified
vesicle fusion (1, 3, 16, 17); the best auspicious prototypes is in support of former (18, 19).
Various readings have projected that manifestation of beige protein can be harmfully control
prelysosomal vesicles or homotypic endosome union, the absenteeism would upsurge combination of
vesicles, ensuing in huge lysosomes (17). Therefore, the appearance of medical indicators connected with the
syndrome is highly connected to the lysosome capacity to combine with organelles (4).
Future study established that LYST protein is
mandatory for the end development of perforin-
comprising particles into secretive cytotoxic particles
(11). Autonomous size, perforin-comprising particles
in CHS. CTLs exhibited an extreme, docked-alike
phenotype at IS but was unable to fuse and degranulate
(11). The identified lytic particle exocytosis effectors
(see Figure 4) are localized in late endosomal sections
and reutilizing in standard CTLs were misguided along
the distended lysosomal organelle present in CHS
CTLs (11). Misguidance of the effectors will result in
perforin-facilitated cytotoxic impairment activity in
CTLs (1) and natural killer (NK) cells, leading to
immune insufficiency and development to HLH.
Genotype–Phenotype association of CHS
Researchers have determined that a resilient phenotype-genotype association is present for CHS with a
characteristic phenotypically heterogeneity. This heterogeneity is specifically dominant in a varying manner
of alteration in the similar CHS1/LYST gene that is evident as considerably changed phenotype (8).
Usually, the complex CHS, accompanied with early inception of the enhanced stage and connected
HLH in infancy, is credited to frame shift, nonsense, or intertwine site alterations leading to vague LYST
protein, whereas the minor type of CHS, accompanied with later inception in middle age and missing the
development of HLH that is accredited to one missense alteration, causing partial function protein (7). The
mentioned varying kinds of alterations connected to LYST gene assembly are portrayed as Figure 3.
Figure 4: the lysosomal–endosomal device is accountable
for intracellular breakdown of internally and externally
produced macromolecules.
6

7CHEDIAK-HIGASHI SYNDROME
Figure 3: The LYST gene in human portrayed in respects to its construction and connected mutational
actions.
Therefore, during the later-inception of CHS it is commonly accredited to similar missense alterations,
protein truncating alterations is recognized not individually in adult type of syndrome, also included in
juvenile variation. Hence, onset interval in people with homozygous shortening alterations are credited to
both genetic and environmental factors (13). Conversely, the recognition of the genuine molecular outcome
during molecular variation is essential to begin a phenotype-genotype association in sufferers owning a dual-
allelic missense alteration (7). The institution of the phenotype-genotype association in respects to CHS
permits for the investigation of the way that give alternation actions distress the appearance of the harsh
LYST gene kind.
Alteration of the CHS1/LYST Gene
By discovering the genotypic centre consisting of phenotypic manifestation of CHS, there is
possibility to extravagant on the phenotypically genetic related with the syndrome (7). The CHS1/LYST gene
encrypts for the lysosomal operating protein, the method of subcellular operation in CHS comprise by the
harm of gene manifestation that has been matter to numerous readings, in an effort to recognize the method
through that procedure may happen (6).
Immune inadequacy frequently demonstrates in those personalities with the complex alternative of the
syndrome, with a tendency to an enhanced stage because of transmissible procedure or bleeding event that
often leads to demise of an individual (10).
While the complexity of CHS have been conventionally separated by phenotypic manifestation in
respects to the syndrome pathogenesis process, CHS is separated on the basis of genotype, endorsing a more
7

8CHEDIAK-HIGASHI SYNDROME
complete analysis. Mainly, this genotypic separation have been recognized through consumption of a CHS
mouse model (7).
A mouse comprising of different “beige” covering colour is used as an ideal in CHS, which was
considered as the chief occurrence for the gene accountable to the disease was recognized (15). 87.9%
homologous behaviour is seen in the LYST/CHS1 gene within murine gene in CHS – denoted as lyst
considered as the mouse prototype of human beige (7).
The examination genotypic alteration degree and the method through which it associates to syndrome
pathogenesis like a phenotypic manifestation permits for separation of CHS, relied on syndrome
rigorousness (16). By creating the phenotype-genotype association in respects to the manifestation of the
harsh kind, the essential foundation is delivered to examine the phenotype-genotype association in the
insignificantly altered allelic set and harshly altered allelic set (7).
Expression, specific cell type, regulation
From the result of the relation among CHS and LYST gene, gene plotting was executed by the
connection readings of CHS. The result exhibited that the CHS gene dwelling might be in 1q distal as the
similar condition in mouse towards CHS offered association to nidogen gene (131390) positioned on 1q
human. The D1S235 indicator achieved the highest lod value (5.38 at theta = 0) by consuming the haplotype
inspection to illustrate D1S163 into the centromere neighbouring indicator and D1S2680 into the telomere
neighbouring indicator (7).
Evaluation of similar coloration alterations in human, mouse and further model creatures result in
arrangement of the current evidence on all coloration genes copied from mouse or human, and noted on three
careful structures (18). A sole family of gene is identified from the connection between melanosomes and
lysosomes, which include LYST and HPS (203300). A robust interruption takes place in antigen exhibition
and peptide stacking onto chief histocompatibility complex (HTC) class II particles in CHS cells of the
sufferers. Categorization of endosomal inhabitant proteins is reliant on the product of CHS1 gene’s for
converting in late endosomes by a technique that includes microtubules (7).
Minor Genotype-phenotype association
Approximately, 15% of CHS sufferers developed an insignificant form of the disorder exhibiting a
different phenotype, while 85% advance a severe definitive form of the syndrome during and post birth (21).
Presently, explanation of 63 CHS1/LYST alterations that comprise 4 acceptor splice positions, 19 deletions,
31 substitutions and 9 insertions (20 non-senses and 11 missense) (19). A noteworthy up-front association
for phenotype and genotype of the disorder is planned: primary reports displays frame shift, splice site and
non-sense mutations resulting in deficiency of CHS1/LYST protein and those linked to acute CHS in infant,
while minor CHS in youngsters and grownups comprise one missense alteration that encrypts a protein
working incompletely (7).
8

9CHEDIAK-HIGASHI SYNDROME
Lysosomal operating controller protein is determined by LYST gene that is included in monitoring the
dimension of vesicles therefore conveying them into the cells. Melanosomes denote to lysosome-alike
vesicles, which occur in melanocytes, whereas the storage and synthesis of melanin previous to activity to
neighbouring keratinocytes (22). Efficient readings including numerous provinces of LYST including the
recognized associating LYST companions intensely exhibit the activity of LYST, in inaugurating the
organelle dimension through regulation of membrane separation actions. The trademark in CHS is addition
of vast bodies in the granulated cells, vast lysosomes together with huge melanosomes. In America, the
clinical indicators of CHS almost ignored the CHS in humans, those inclined to progress a
lymphoproliferative disease in the augmented phase. Separately from the distinction, the idea that CHS
indicators in mink is not simply identified as linked from the humans may be accredited to the opinion that
contamination revelation is low as the mink farmhouses are typically sheltered from syndromes (22).
CHS1 protein action is principally unidentified; though, there is exhibition of distended lysosomes
along with lysosome-focused organelles in all types of cells in CHS sufferers. Modern functional
investigation on numerous provinces of CHS1 and its cooperating associates with v-SNARES intensely
specify CHS1 character in identifying the organelle dimension over instruction of membrane separation and
separation actions (23).
Numerous clinical phenotypes of CHS is correlated with molecular genotyping as compared to
missense alterations are related to minor, late-inception CHS having sluggish advanced neurological
imperfection, or the youthful type that has contaminations but deficit of haemophagocytic lympohistiocytosis
(23).
Late-inception neural dysfunction
A neurodegenerative advanced disorder enclosing exceptional pigmentary deficiencies and missing
subclinical invulnerable deficiencies known as late-inception CHS. The mentioned CHS holds for 10-15%
for all CHS patients; though, the number can be increased (20). Neurologic indications likely to fluctuate, but
occasionally encompass of Parkinsonism, ataxia, peripheral neuropathy and intellectual reduction. The
people with genotype including the mentioned phenotypes resulted in four genotypes, which result in
LYST/CHS; consisting missense alterations (24). CHS murine models comprising homozygous alterations of
missense in the LYST exhibit various neurologic phenotypes like inferior motor functionality marks equated
to standards, with assortment of huge lysosomes within cellular neurons associated with intracytoplasmic
combination in Purkinje cells consisting of cerebellum and motor cortex. Through autopsy, the adult patient
with CHS exhibit a failure in neurons that included the fragile olivary nuclei together with the cerebellar
cortex, joined with a whole dispersal that is similar to OPCA (olivopontocerebellar atrophy) and LCCA (late
cortical cerebellar atrophy) without any pontine participation (25).
Three grownup siblings was utilized to demonstrate a separate type of Chediak-Higashi disease acting
with neurodegenerative development disorder and partaking minor immunological imperfections, associated
9

10CHEDIAK-HIGASHI SYNDROME
with unusual coloration (24). The patients displayed neuropsychological insufficiencies like attention-deficit
behaviours and learning problems that may have significantly preceded the commencement of free
neurologic signs. Additionally, traditional CHS is related to learning difficulties in lawbreakers, and further
to advanced, dispersed white matter imperfections on MRI joined with neurologic decline and amplified
worsening in immunity or resistance. The family encompasses CHS phenotype through contributing more
description for the syndromes connected with the CNS of the patients. Irregular CHS is considered
phenotypically dissimilar and must be taken in account during growth of neurodegenerative disorder escorted
by pigmentary deficiencies in young grown-ups. The syndrome can be separated easily by distinguishing
outcomes from marginal blood slur and hair selection, even if these are not common as related to standard
CHS phenotypes (24).
The early-inception phenotype is categorized by the inclination to create an ‘enhanced phase’
The early-inception phenotype is categorized by the inclination to create an ‘enhanced phase’, a lymph
proliferative penetration of the reticuloendothelial system and bone marrow that relates to the scientific
depiction of HLH (1, 25, 26). HLH might take place immediately after or few years of birth (27) and is
described by an extremely enthused, but unsuccessful, immune reaction to antigens, causing a dangerous
cytokine hurricane and inflammatory response (1). The granule-reliant cytotoxic path of CTLs and NK cells
is the crucial equipment in the sanction of intracellular and viral bacterial contaminations, including the
tumour growth prevention (11). This comprises cytotoxic particle biogenesis and end development, operating
to IS, priming, cutting, and blending with plasma membrane (PM) to adapt secretion capability (see Figure 5)
(11). In a fit person, the above cytotoxic particles comprising perforin, supplemented by granzymes, which
facilitate apoptotic demise of the target cells tailed by directive of immune reaction (28). HLH is connected
with an overexcited adaptive immune structure, possibly resultant due to disaster of stimulated NK cells and
CTLs to remove antigen-presenting cells (APCs), therefore, miscarry to stop the immune reaction. This
effects from the issue of perforin or unsuccessful biogenesis, the crucial cytotoxic moderator (29).
Figure 5: Schematic illustration of HLHs with their faulty genes.
10

11CHEDIAK-HIGASHI SYNDROME
Unrestrained growth as well as initiation of polyclonal
CTLs in HLH results in initiation of macrophages that
release harmful pro-inflammatory cytokines (Figure 6)
(3). The children with CHS live upto is six years
(27). The transplantation of bone marrow is only
operative treatment which is successful only before the
time when patient displaying the “accelerated phase”
(30). Hence, expectancy of the accelerated segment is
crucial for prediction, and it is dependent on gene and
phenotype associations.
Mutation induced a truncating protein caused
‘severe’ phenotype
Homozygous protein-null allele is observed in
patient with this phenotype (see Table 1). One study
reported two homozygous alterations, at codons
Lys633/Lys634 with a single base insertion (adenine) causes frame shift followed by at codon 638 premature
translational termination. These alterations facilitate the distinctive ‘severe’ phenotype in all the stage, e.g.
childhood inception as well as progress of the enhanced phase. Significant number of reported cases
suggested that heterozygous alterations ensuing in severe phenotype (see Table 1).
Table 1. CHS1 alterations and result on CHS1 protein
Genotype Effect on
LYST mRNA mRNA Refere
nce Genotype Effect on
LYST mRNA mRNA Refere
nce
Homozyg
ous
Nonsense/
frameshift
c.1467del
G (32) Homozyg
ous Missense c.2570C > G (29)
Homozyg
ous
Nonsense/
frameshift
c.1899ins
A
c.10395de
lA
c.6078C
> A
(31) Compoun
d
Nonsense/
frameshift c.9930delT (29)
Homozyg
ous
Nonsense/
frameshift
c.9590del
A
(26, 31,
33)
Compoun
d
heterozyg
ous
Nonsense/
frameshift c.1540C > T (34)
Figure 6: in a normal individual and in a patient with
haemophagocyticlymphohistiocytosis, an antigen-specific CD8+ T
cell response to viral infection.
11

12CHEDIAK-HIGASHI SYNDROME
Homozyg
ous
Nonsense/
frameshift
c.3085C
> T
c.2620del
T
(33, 35)
Compoun
d
heterozyg
ous
Nonsense/
frameshift c.3622C > T (30)
Homozyg
ous
Nonsense/
frameshift
c.2620del
T
c.10395de
lA
(31, 33,
35)
Heterozyg
ous
Nonsense/
frameshift
c.5317delA
c.9228ins
10 bp
(33)
Homozyg
ous
Nonsense/
frameshift
c.7060-
7066del
7 bp
c.5519del
C
c.5004del
A
(26) Heterozyg
ous
Nonsense/
frameshift c.7060-1G > T (29)
Homozyg
ous
Nonsense/
frameshift
c.5506C
> T (33) Heterozyg
ous
Nonsense/
frameshift
c.3944-
3945insC (12)
Homozyg
ous
Nonsense/
frameshift
c.11102G
> T (36) Heterozyg
ous
Nonsense/
frameshift
c.2454delA
c.3434-
3435insA
c.4052C > G
(31)
Homozyg
ous
Nonsense/
frameshift
c.7555del
T c.9106-
9161del
56 bp
c.3310C
> T
(37) Homozyg
ous
Nonsense/
frameshift
c.4508C > G
c.5506C > T
c.5506C > T
c.7060-1G > A
c.10551_1055
2del2
c.2374_2375d
elGA
(29)
Homozyg
ous
Nonsense/
frameshift
c.925C >
T (38)
Discrepancies with the current phenotypic-genotypic correlation
While numerous cases suggested easy phenotype-genotype association in CHS, several suggested
no clear association is observed (7, 12, 26, 29, 33, 36). A study highlighted four diverse homozygous
alterations induces premature stop codons ,a single bp removal in exon 17 [c.5004delA]) and single bp
removal in exon 20 [c.5519 delC]. Every patients having the typical as well severe juvenile form of CHS
have the fourth. These patients have development delay with no harmful infections. However, without
12

13CHEDIAK-HIGASHI SYNDROME
growth of an accelerated phase, it is similar to the teenage form of CHS (26). On the other hand, the
researchers of another study informed that two siblings having the same homozygous alteration in the
LYST gene, exhibited two different phenotypes(36). While accelerated phase was observed for sister at the
age of four followed by a Salmonella infection, her brother showed an influenza infection at early stages
with severe phenotype and her brother died at the age of 5 (36). A analogous clinical case was observed
having six homozygous alterations caused truncations of the LYST protein, where one patient shared the
same gene alterations which was found in earlier reported case of patient with late-onset disease (33).
13

14CHEDIAK-HIGASHI SYNDROME
Epigenetic factors are defined as changes in functionality of genes as well as expression without
mutating the original DNA sequence. Considering the impacts of physiological factors, these markers are
vital for packaging and understanding the genome (37). Epigenetic research enables researchers to elucidate
mechanism of differentiation of cells carrying identical DNA, into two different cell types and maintenance
of it. In response environmental stimuli, epigenetic modifications observed as a result of dynamic process
regulated by cascade mechanism (39). For environmental stimuli, truncating alterations of protein have been
observed in patients with the adult-onset form of the disease (7, 29).
A study suggested that the mutant protein is a dominant negative. Literature documented that deletion
( mutation ) of carboxyl WD40 domain induce the dominant negative phenotype (14) which further
highlighted that alterations of these regions may inhibit the protein which is produced in normal allele.
This phenomenon further explained despite the presence of autosomal inheritance pattern why
heterozygotes are affected.
Researchers highlighted that CHS is congenital in patient in an autosomal recessive method. Hence,
both paternities of diseased child have heterozygotes in asymptomatic manner (7). However, many
researchers reported that uniparentaldisomy of chromosome 1give rise to CHS (35, 37). In case of an
affected child, genes with polymorphic DNA markers from 1q43 discovered which is inherited a maternal
haplotype but have no paternal haplotype. In heterozygous alteration in the mother’s DNA, a homozygous
base pair deletion was identified in the LYST gene which led to premature stop codon but it was not present
in the father’s (35). Moreover, non-disjunction events during meiosis I or II in one parent which result in
gamete complementation. Moreover, trisomy rescue which will result will heterodisomy(44). The trisomy
observed in later studies.
The association between alteration within the gene and the clinical severity of CHS is not observed
since researchers indicated no preference for region of alterations in specific part of the CHS1 gene is
observed(12). An initial study also determined that phenotype of this disease has no association with length
of that truncated protein (33).
An ‘immunophenotype’-genotype association, manifestation of disease:
While platelet granules are often found in platelets of late-onset disease , platelets of patients having
“childhood” CHS markedly lacked in dense bodies (7, 23, 25, 30, 34, 37), CHS(7, 25). High association
between disease phenotype and in CTLs the amount of lytic impairment also observed , indicating for
clinical decisions, an ‘immunophenotype’-genotype association is useful (7). While CHS patients have early-
onset HLH shows reduced CLT cytotoxicity, the normal amount is observed in patient patients with late
stage of HLH (7). This suggests that minor change or difference in functionality of CTL can regulate
whether an infection will activate full HLH or eliminate without showing symptoms of disease (29).
14

15CHEDIAK-HIGASHI SYNDROME
Attribution of Authorship
In this study, the abstract as well as introduction were authored by student name; the title page as well as
mild genotype-phenotype and neurologic incapability were authored by student name; the acute genotype-
phenotype as well as inclusion were authored by student name.
15

16CHEDIAK-HIGASHI SYNDROME
References
1.Ji X, Chang B, Naggert JK, Nishina PM. Lysosomal trafficking regulator (LYST). InRetinal Degenerative
Diseases 2016 (pp. 745-750). Springer, Cham.
2. Jhaveri A, Torchilin V. Intracellular delivery of nanocarriers and targeting to subcellular organelles.
Expert opinion on drug delivery. 2016 Jan 2;13(1):49-70.
3. Ammann S, Lehmberg K, zur Stadt U, Janka G, Rensing‐Ehl A, Klemann C, Heeg M, Bode S, Fuchs I,
Ehl S, HLH study of the GPOH. Primary and secondary hemophagocytic lymphohistiocytosis have different
patterns of T‐cell activation, differentiation and repertoire. European journal of immunology. 2017
Feb;47(2):364-73.
4. Gil-Krzewska A, Wood SM, Murakami Y, Nguyen V, Chiang SC, Cullinane AR, Giovanna P, Gahl WA,
Coligan JE, Introne WJ, Bryceson YT. Chediak-Higashi syndrome: LYST domains regulate exocytosis of
lytic granules, but not cytokine secretion by NK cells. The Journal of allergy and clinical immunology. 2016
Apr;137(4):1165.
5.Toro C, Nicoli ER, Malicdan MC, Adams DR, Introne WJ. Chediak-Higashi Syndrome.
InGeneReviews®[Internet] 2018 Jul 5. University of Washington, Seattle
6.Palaniyandi S, Sivaprakasam E, Pasupathy U, Ravichandran L, Rajendran A, Suman FR, Rajendra Prasad
S. Chediak-Higashi syndrome presenting in the accelerated phase. South African Journal of Child Health.
2017 Jun; 11(2):104-6.
7.Gil-Krzewska A, Saeed MB, Oszmiana A, Fischer ER, Lagrue K, Gahl WA, Introne WJ, Coligan JE,
Davis DM, Krzewski K. An actin cytoskeletal barrier inhibits lytic granule release from natural killer cells in
patients with Chediak-Higashi syndrome. Journal of Allergy and Clinical Immunology. 2018 Sep
1;142(3):914-27.
8.Roche JV, Survery S, Kreida S, Nesverova V, Ampah-Korsah H, Gourdon M, Deen PM, Törnroth-
Horsefield S. Phosphorylation of human aquaporin 2 (AQP2) allosterically controls its interaction with the
lysosomal trafficking protein LIP5. Journal of Biological Chemistry. 2017 Sep 1;292(35):14636-48.
9.Xu X, Shen W. 2013.
10. Helmi, M. M., Saleh, M., Yacop, B., & ElSawy, D. (2017). Chédiak-Higashi syndrome with novel gene
mutation. BMJ case reports, 2017, bcr2016216628.'
11. Lawrence RE, Zoncu R. The lysosome as a cellular centre for signalling, metabolism and quality control.
Nat. Cell Biol. 2019 Jan 2.
12.Tanabe F, Kasai H, Morimoto M, Oh S, Takada H, et al. 2010. Case reports in medicine 2010
13. Bowman SL, Bi‐Karchin J, Le L, Marks MS. The road to LROs: insights into lysosome‐related
organelles from Hermansky‐Pudlak syndrome and other rare diseases. Traffic. 2019 Apr 4.
16

17CHEDIAK-HIGASHI SYNDROME
14. Balak C, Belnap N, Ramsey K, Joss S, Devriendt K, Naymik M, Jepsen W, Siniard AL,
Szelinger S, Parker ME, Richholt R. A novel FBXO28 frameshift mutation in a child with
developmental delay, dysmorphic features, and intractable epilepsy: A second gene that may
contribute to the 1q41‐q42 deletion phenotype. American Journal of Medical Genetics Part A. 2018
Jul;176(7):1549-58.
15. Westphal A. Lysosomal trafficking regulator Lyst controls innate immune cell signalling and function:
regulation of TLR-mediated TRIF signalling and control of mast cell-mediated allergic reactions (Doctoral
dissertation, Medizinische Hochschule Hannover).
16.Lie PP, Nixon RA. Lysosome trafficking and signaling in health and neurodegenerative diseases.
Neurobiology of disease. 2018 May 30
17. Steffens A, Jakoby M, Hülskamp M. Physical, Functional and Genetic Interactions between the BEACH
Domain Protein SPIRRIG and LIP5 and SKD1 and Its Role in Endosomal Trafficking to the Vacuole in
Arabidopsis. Frontiers in plant science. 2017 Nov 20;8:1969.
18.Hwang YH, Conklin J, Chan W, Roslin NM, Liu J, He N, Wang K, Sundsbak JL, Heyer CM, Haider M,
Paterson AD. Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease.
Journal of the American Society of Nephrology. 2016 Jun 1;27(6):1861-8.
19.Terlizzi V, Castaldo G, Salvatore D, Lucarelli M, Raia V, Angioni A, Carnovale V, Cirilli N, Casciaro R,
Colombo C, Di Lullo AM. Genotype–phenotype correlation and functional studies in patients with cystic
fibrosis bearing CFTR complex alleles. Journal of medical genetics. 2017 Apr 1; 54(4):224-35.
20. Lefroy H, Fox O, Javaid MK, Makaya T, Shears DJ. 1q24 deletion syndrome. Two cases and new
insights into genotype‐phenotype correlations. American Journal of Medical Genetics Part A. 2018 Sep;
176(9):2004-8.
21.Sajjad R, Arif R, Shah AA, Manzoor I, Mustafa G. Pathogenesis of Alzheimer's Disease: Role of
Amyloid-beta and Hyperphosphorylated Tau Protein. Indian Journal of Pharmaceutical Sciences. 2018 Jul
31; 80(4):581-91.
22.Ayalew LE, Gupta A, Fricke J, Ahmed KA, Popowich S, Lockerbie B, Tikoo SK, Ojkic D, Gomis S.
Phenotypic, genotypic and antigenic characterization of emerging avian reoviruses isolated from clinical
cases of arthritis in broilers in Saskatchewan, Canada. Scientific reports. 2017 Jun 15;7(1):3565.
23.Scherber E, Beutel K, Ganschow R, Schulz A, Janka G, zur Stadt U. 2009. Clinical genetics 76: 409-12
24.Kanjanapongkul S. 2006. JOURNAL-MEDICAL ASSOCIATION OF THAILAND 89: 541
25.Palaniyandi S, Sivaprakasam E, Pasupathy U, Ravichandran L, Rajendran A, Suman FR, Rajendra Prasad
S. Chediak-Higashi syndrome presenting in the accelerated phase. South African Journal of Child Health.
2017 Jun; 11(2):104-6.
17

18CHEDIAK-HIGASHI SYNDROME
26. Introne WJ, Westbroek W, Cullinane AR, Groden CA, Bhambhani V, Golas GA, Baker EH, Lehky TJ,
Snow J, Ziegler SG, Adams DR. Neurologic involvement in patients with atypical Chediak-Higashi disease.
Neurology. 2016 Apr 5; 86(14):1320-8.
27. Kishore M, Marwah S, Kumar V, Suteri P, Nigam AS. Accelerated Phase of Chediak Higashi Syndrome:
An Unusual Case of Pancytopenia. Annals of Pathology and Laboratory Medicine. 2016 Aug 24;3(3):C156-
160.'
28. Maaloul I, Talmoudi J, Chabchoub I, Ayadi L, Kamoun TH, Boudawara T, Kallel CH, Hachicha M.
Chediak–Higashi syndrome presenting in accelerated phase: A case report and literature review.
Hematology/oncology and stem cell therapy. 2016 Jun 1; 9(2):71-5.
29.Nagle DL, Karim MA, Woolf EA, Holmgren L, Bork P, et al. 1996. Nature genetics 14: 307-11
30.Certain S, Barrat F, Pastural E, Le Deist F, Goyo-Rivas J, et al. 2000. Blood 95: 979-83
31.Wu XL, Zhao XQ, Zhang BX, Xuan F, Guo HM, Ma FT. A novel frameshift mutation of Chediak-
Higashi syndrome and treatment in the accelerated phase. Brazilian Journal of Medical and Biological
Research. 2017; 50(4).
32.Karaman K, Akbayram S, Geylan H, Çetin M. Chediak-Higashi syndrome presented with
hemophagocytic lymphohistiocytosis. Indian Journal of Medical and Paediatric Oncology. 2018; 39(1).
33.Kaya Z, Ehl S, Albayrak M, Maul‐Pavicic A, Schwarz K, et al. 2011. Pediatric blood & cancer 56: 1136-
9
34.Jaiswal P, Yadav YK, Bhasker N, Kushwaha R. Accelerated Phase of Chediak-Higashi Syndrome at
Initial Presentation: A Case Report of an Uncommon Occurrence in a Rare Disorder. Journal of Clinical and
Diagnostic Research: JCDR. 2015 Dec;9(12):ED13.
35.Al-Tamemi S, Al-Zadjali S, Al-Ghafri F, Dennison D. 2014. Journal of pediatric hematology/oncology
36: e248-e50
36.Jin Y, Zhang L, Wang S, Chen F, Gu Y, Hong E, Yu Y, Ni X, Guo Y, Shi T, Xu Z. Whole Genome
Sequencing Identifies Novel Compound Heterozygous Lysosomal Trafficking Regulator Gene Mutations
Associated with Autosomal Recessive Chediak-Higashi Syndrome. Scientific reports. 2017 Feb 1;7:41308.
37. Desai N, Weisfeld-Adams JD, Brodie SE, Cho C, Curcio CA, Lublin F, Rucker JC. Optic neuropathy in
late-onset neurodegenerative Chédiak–Higashi syndrome. British Journal of Ophthalmology. 2016 May
1;100(5):704-7.
38. Garg A, Nigwekar P, Shrikhande D, Kumar CA, Singh V, Singh A. Chediak-Higashi Syndrome: A Rare
Case Report. Pravara Medical Review. 2015 Sep 1;7(2).
39. Shirazi TN, Snow J, Ham L, Raglan GB, Wiggs EA, Summers AC, Toro C, Introne WJ. The
neuropsychological phenotype of Chediak-Higashi disease. Orphanet Journal of Rare Diseases. 2019
Dec;14(1):101.
18

19CHEDIAK-HIGASHI SYNDROME
19